Literature DB >> 21305819

Medication assistance programs: do all in need benefit equally?

Maria Pisu1, Katie Crenshaw, Ellen Funkhouser, Midge Ray, Catarina I Kiefe, Kenneth Saag, Cynthia LaCivita, Jeroan J Allison.   

Abstract

OBJECTIVE: To determine if medication assistance programs (MAPs) provided by pharmaceutical companies were used differently by African Americans and Whites. RESEARCH
DESIGN: A cross-sectional survey was conducted among patients of primary care practices from 2005 to 2007 within the Alabama Nonsteroidal Anti-Inflammatory Drug (NSAID) Patient Safety Study.
SETTING: Telephone survey. PARTICIPANTS: Respondents were 568 African American and White patients reporting annual household incomes < $50,000. MAIN OUTCOME MEASURE: Use of MAPs.
RESULTS: Of all patients, 12.8% used MAPs, 39.5% were African American, 75.2% were female, 69.1% were aged > 65 years, 79.8% had annual household incomes < $25,000, and 35.5% indicated that their income was inadequate to meet their basic needs. MAPs were used by 11.2% African-Americans and 14.0% Whites. After multivariable adjustment, MAP use was higher among respondents with incomes not adequate to meet basic needs (odds ratio [OR]: 2.19, 95% confidence interval [CI]: 1.17-4.08) but lower among African Americans than Whites (OR: 0.49, 95% CI: 0.25-0.95). Physician characteristics did not independently predict MAP use.
CONCLUSIONS: Overall MAP use was low even among the most vulnerable, and especially among African Americans. As currently used, MAPs may contribute to disparities in medication access.

Entities:  

Mesh:

Year:  2010        PMID: 21305819      PMCID: PMC3854657     

Source DB:  PubMed          Journal:  Ethn Dis        ISSN: 1049-510X            Impact factor:   1.847


  21 in total

1.  Use of drug manufacturers' patient assistance programs by safety net providers.

Authors:  Katheryne Richardson; Lorne E Basskin
Journal:  Am J Health Syst Pharm       Date:  2002-06-01       Impact factor: 2.637

2.  A 12-Item Short-Form Health Survey: construction of scales and preliminary tests of reliability and validity.

Authors:  J Ware; M Kosinski; S D Keller
Journal:  Med Care       Date:  1996-03       Impact factor: 2.983

3.  Patient-assistance programs: assessment of and use by safety-net clinics.

Authors:  Kathryn Saenz Duke; Kristiana Raube; Helene Levens Lipton
Journal:  Am J Health Syst Pharm       Date:  2005-04-01       Impact factor: 2.637

4.  Effects of a medication assistance program on health outcomes in patients with type 2 diabetes mellitus.

Authors:  Matthew W Strum; Robert Hopkins; Donna S West; Brittany N Harris
Journal:  Am J Health Syst Pharm       Date:  2005-05-15       Impact factor: 2.637

5.  Impact of the cost of prescription drugs on clinical outcomes in indigent patients with heart disease.

Authors:  M D Schoen; R J DiDomenico; S E Connor; J E Dischler; J L Bauman
Journal:  Pharmacotherapy       Date:  2001-12       Impact factor: 4.705

6.  Patient-reported communications with pharmacy staff at community pharmacies: the Alabama NSAID Patient Safety Study, 2005-2007.

Authors:  Cynthia LaCivita; Ellen Funkhouser; Michael J Miller; Midge N Ray; Kenneth G Saag; Catarina I Kiefe; Daniel J Cobaugh; Jeroan J Allison
Journal:  J Am Pharm Assoc (2003)       Date:  2009 Sep-Oct

7.  The limitation of good intentions: prescribing medications for the uninsured.

Authors:  Todd D Sorensen; John Song; Sarah M Westberg
Journal:  J Health Care Poor Underserved       Date:  2004-05

8.  Cost-lowering strategies used by medicare beneficiaries who exceed drug benefit caps and have a gap in drug coverage.

Authors:  Chien-Wen Tseng; Robert H Brook; Emmett Keeler; W Neil Steers; Carol M Mangione
Journal:  JAMA       Date:  2004-08-25       Impact factor: 56.272

9.  Impact of an annual dollar limit or "cap" on prescription drug benefits for Medicare patients.

Authors:  Chien-Wen Tseng; Robert H Brook; Emmett Keeler; Carol M Mangione
Journal:  JAMA       Date:  2003-07-09       Impact factor: 56.272

Review 10.  Pharmacist-facilitated enrollment in medication assistance programs in a private ambulatory care clinic.

Authors:  Mahnaz Sarrafizadeh; Nancy M Waite; Eric H Hobson; Hedy Migden
Journal:  Am J Health Syst Pharm       Date:  2004-09-01       Impact factor: 2.637

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.